Skip to main content
SpringerLink
Log in

Pathology of Serous Tumors

  • Chapter
  • First Online:
Diagnostic Pathology of Ovarian Tumors

Abstract

Serous tumors are separable into benign serous tumors, serous borderline tumor, high-grade serous carcinomas (HGSC), and low-grade serous carcinomas (LGSC). This chapter discusses the prevalence, macroscopic and microscopic features, differential diagnoses, treatment options, and clinical outcomes of each of these tumor types.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223–8.

    Article  PubMed  CAS  Google Scholar 

  2. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;2:218–24.

    Google Scholar 

  3. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;5:267–82.

    Article  Google Scholar 

  4. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for gradinig ovarian serous carcinoma. Am J Surg Pathol. 2007;31:1168–74.

    Article  PubMed  Google Scholar 

  5. Szyfelbein WM, Young RH, Scully RE. Cystic struma ovarii: a frequently unrecognized tumor. A report of 20 cases. Am J Surg Pathol. 1994;18:785–8.

    Article  PubMed  CAS  Google Scholar 

  6. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–8.

    Article  PubMed  Google Scholar 

  7. Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol. 1988;72:775–81.

    PubMed  CAS  Google Scholar 

  8. Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic ­surface tumor to peritoneal “implants”. Am J Surg Pathol. 1992;16((6):577–83.

    Article  Google Scholar 

  9. Gilks CB, Alkushi A, Yue J, et al. Advanced stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol. 2003;22:29–36.

    Article  PubMed  Google Scholar 

  10. Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006;30:1367–71.

    Article  PubMed  Google Scholar 

  11. Shvartsman HS, Sun CC, Bodurka DC, et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007;105:625–9.

    Article  PubMed  Google Scholar 

  12. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or  =  5-year) follow-up. Am J Surg Pathol. 2005;29:707–23.

    Article  PubMed  Google Scholar 

  13. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal microinvasion in ovarian serous tumors of low malignant potential ­(borderline tumors): a reevaluation of the concept of stromal microinvasion. Am J Surg Pathol. 2006;30:1209–21.

    Article  PubMed  Google Scholar 

  14. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low-malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol. 2006;30:614–24.

    Article  PubMed  Google Scholar 

  15. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999;23:397–409.

    Article  PubMed  CAS  Google Scholar 

  16. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade serous carcinoma. J Natl Cancer Inst. 2003;95:484–6.

    Article  PubMed  CAS  Google Scholar 

  17. Bell DA, Longacre TA, Prat J, et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol. 2004;35:934–48.

    Article  PubMed  Google Scholar 

  18. Sangoi AR, Soslow RA, Teng NN, et al. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol. 2008;32:269–74.

    Article  PubMed  Google Scholar 

  19. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203–11.

    Article  PubMed  Google Scholar 

  20. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;1:1–7.

    Article  CAS  Google Scholar 

  21. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26(25):4160–5.

    Article  PubMed  Google Scholar 

  22. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 2009;19(1):58–64.

    Article  PubMed  Google Scholar 

  23. Köbel M, Kalloger SE, Santos JE, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2010;116:50–6.

    Article  PubMed  Google Scholar 

  24. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, et al. Neoadjuvant chemotherapy or primary surgery in Stage IIIc-IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  PubMed  CAS  Google Scholar 

  25. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.

    Article  PubMed  Google Scholar 

  26. Soslow RA, Rouse RV, Hendrickson MR, et al. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. Int J Gynecol Pathol. 1996;15:257–65.

    Article  PubMed  CAS  Google Scholar 

  27. Han G, Gilks CB, Leung S, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol. 2008;7:955–64.

    Google Scholar 

  28. Miller K, Price JH, Dobbs SP, et al. An immunhistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol. 2008;61:652–7.

    Article  PubMed  CAS  Google Scholar 

  29. Hennessy BT, Timms KM, Carey MS, et al. omatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570–6. Epub ahead of print.

    Article  PubMed  Google Scholar 

  30. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.

    Article  PubMed  CAS  Google Scholar 

  31. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49–56.

    Article  PubMed  CAS  Google Scholar 

  32. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1–9.

    Article  PubMed  Google Scholar 

  33. Köbel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 2008;10:e22.

    Article  PubMed  Google Scholar 

  34. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.

    Article  PubMed  Google Scholar 

  35. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2005;46:468.

    Article  Google Scholar 

  36. Gilks CB, Ionescu D, Kalloger S, et al. Tumor cell type can be reproducibly diagnosed and is of independent significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239–51.

    Article  PubMed  CAS  Google Scholar 

  37. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14–21.

    Article  PubMed  Google Scholar 

  38. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol. 1990;3(2):120–8.

    PubMed  CAS  Google Scholar 

  39. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109–15.

    Article  PubMed  CAS  Google Scholar 

  40. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of British Columbia/Vancouver General Hospital, Vancouver, BC, V5Z 4E3, Canada

    C. Blake Gilks M.D., F.R.C.P.C.

Authors
  1. C. Blake Gilks M.D., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Pathology, Memorial Sloan-Kettering Cancer Center, York Ave. 1275, NEW YORK, 10021, New York, USA

    Robert A. Soslow

  2. SUNY Stony Brook, Department of Pathology, Stony Brook Univ Medical Center, Hospital Level 2, Room 766, Stony Brook, 11794-7025, New York, USA

    Carmen Tornos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gilks, C.B. (2011). Pathology of Serous Tumors. In: Soslow, R., Tornos, C. (eds) Diagnostic Pathology of Ovarian Tumors. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9751-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9751-7_6

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9750-0

  • Online ISBN: 978-1-4419-9751-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation